What is Fibroblast?
Fibroblast operates as a referral management platform designed to rectify the fragmented referral process within healthcare organizations. By equipping providers with intuitive, end-to-end tools, the platform actively manages patient referrals. This comprehensive approach aims to prevent patient leakage, a critical issue that erodes revenue for fee-for-service models. Furthermore, it mitigates risks for accountable care organizations, thereby delivering a demonstrable return on investment. The company's focus on closing the referral loop positions it as a key player in enhancing operational efficiency and financial performance for healthcare providers.
How much funding has Fibroblast raised?
Fibroblast has raised a total of $2.9M across 3 funding rounds:
Private Equity
$727K
Private Equity
$2M
Debt
$150K
Private Equity (2013): $727K, investors not publicly disclosed
Private Equity (2018): $2M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
What's next for Fibroblast?
The substantial enterprise-level funding and recent strategic investment signal a new phase of growth and development for Fibroblast. This capital infusion is expected to fuel product innovation, expand market reach, and enhance the platform's capabilities in managing complex referral networks. Fibroblast is poised to further solidify its position in the healthcare technology sector, addressing the critical need for streamlined patient pathways and improved revenue cycle management. The company's trajectory suggests a continued focus on empowering healthcare providers with advanced tools to navigate the evolving landscape of value-based care.
See full Fibroblast company page
